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Background—Studies conflict regarding the importance of the fluoroquinolone-resistant North 
American pulsed-field gel electrophoresis type 1 (NAP1) strain in Clostridium difficile infection 
(CDI) outcome. We describe strain types causing CDI and evaluate their association with patient 
outcomes.
Methods—CDI cases were identified from population-based surveillance. Multivariate 
regression models were used to evaluate the associations of strain type with severe disease (ileus, 
toxic megacolon, or pseudomembranous colitis within 5 days; or white blood cell count 
≥15,000/mm3 within one day of positive test), severe outcome (intensive care unit admission after 
positive test, colectomy for C. difficile infection, or death within 30 days of positive test), and 
death within 14 days of positive test.
Results—Strain typing results were available for 2,057 cases. Severe disease occurred in 363 
(17.7%) cases, severe outcome in 100 (4.9%), and death within 14 days in 56 (2.7%). The most 
common strain types were NAP1 (28.4%), NAP4 (10.2%) and NAP11 (9.1%). In unadjusted 
analysis, NAP1 was associated with greater odds of severe disease than other strains. After 
controlling for patient risk factors, healthcare exposure, and antibiotic use, NAP1 was associated 
with severe disease (adjusted odds ratio [aOR] 1.74, 95% confidence interval [CI], 1.36–2.22), 
severe outcome (aOR 1.66, 95% CI, 1.09–2.54), and death within 14 days (aOR 2.12, 95% CI, 
1.22–3.68).
Conclusion—NAP1 was the most prevalent strain and a predictor of severe disease, severe 
outcome, and death. Strategies to reduce NAP1 prevalence, such as antibiotic stewardship to 
reduce fluoroquinolone use, might reduce CDI morbidity.
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INTRODUCTION
Increases in incidence and severity of Clostridium difficile infection (CDI) have been 
reported in the past decade and were initially attributed to the emergence of a 
“hypervirulent” strain, the North American pulsed field gel electrophoresis type 1 (NAP1) 
strain, also described as PCR ribotype 027 and restriction endonuclease analysis (REA) 
group BI [1–3]. This strain demonstrates increased toxin production in vitro and increased 
fluoroquinolone resistance compared to previously described strains.
Subsequent reports of the relationship between the NAP1 strain and patient outcomes have 
conflicted. Although some suggest that infection with the NAP1 strain is associated with 
more severe disease [4–6], others reported no association [7–11]. These studies used 
different outcome measures (clinical severity [10] as defined by clinical practice guidelines 
[12]; a composite of intensive care unit admission, colectomy, and death [5, 7, 9]; and 14 or 
30-day mortality [4, 6, 8, 11]), involved small sample sizes, or have focused on cases of 
infection from a single institution or community.
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We sought to clarify the role of C. difficile strain type by determining the relationship 
between strain type and disease outcomes using a geographically diverse dataset from the 
United States (US). We used outcome measures similar to those in other studies to facilitate 
comparisons with prior reports.
METHODS
CDI Surveillance and Study Population
Data were obtained from the Centers for Disease Control and Prevention (CDC)’s Emerging 
Infections Program (EIP) C. difficile surveillance, which has been described elsewhere [13, 
14]. The EIP CDI surveillance system is an active population-based and laboratory-based 
surveillance system that began in 2009 in selected counties of 6 US states (California, 
Colorado, Connecticut, Georgia, Minnesota, New York), expanded to 2 additional US states 
in 2010 (Tennessee and Oregon), and in 2011 expanded to an additional 2 states (Maryland 
and New Mexico). At each EIP site, trained surveillance officers investigate all positive C. 
difficile toxin assay or molecular assay reports from clinical, reference, and commercial 
laboratories for residents of surveillance catchment areas. A CDI case is defined as a 
positive C. difficile stool specimen in a surveillance area resident aged one year or older who 
did not have a positive test in the previous 8 weeks.
Cases are classified as community-associated if a positive specimen was collected as an 
outpatient or within 3 days of an acute care admission, without documentation of an 
overnight stay in a healthcare facility during the 12 weeks prior to stool collection; 
otherwise, cases are classified as healthcare-associated. Healthcare-associated cases are 
further classified as healthcare facility-onset if they occurred during a long-term care 
facility/nursing home stay or > 3 calendar days after hospital admission; otherwise they are 
classified as community-onset healthcare facility-associated [15]. All CDI cases classified as 
either community-associated or community-onset healthcare-facility associated underwent a 
full medical record review to collect information on symptoms, co-infections, clinical 
comorbidities (Charlson index) [16], and outcomes, and a 10% sample of the healthcare 
facility-onset cases were fully reviewed.
A convenience sample of clinical laboratories in each catchment area (n=37 laboratories) 
submitted all stool specimens from CDI cases with full medical record review to three 
reference laboratories (Edwards Hines Jr. Veterans Affairs, New York State Department of 
Health, and Minnesota Department of Health Public Health Laboratory) for culture of C. 
difficile [17]. Recovered isolates were sent to CDC for molecular typing by pulsed-field gel 
electrophoresis (PFGE). PFGE patterns were analyzed using BioNumerics v.5.10 (Applied 
Maths, Austin, TX) and grouped into pulsed-field types using Dice/UPGMA clustering. An 
80% similarity threshold was used to assign North American PFGE (NAP) types [18]. 
Isolates also underwent PCR to detect the presence of tcdA, tcdB and binary toxin (cdtA and 
ctdB) genes [19].
For this analysis, we limited the data to the CDI cases with stool specimens collected 
between January 1, 2009–December 31, 2011. Only cases with full medical record review 
and strain typing results available were included. Cases whose isolates were negative for 
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both tcdA and tcdB (89 cases) were excluded. During 2009–2011, only 8 EIP sites collected 
stool specimens (CA, CO, CT, GA, MN, NY, OR, and TN). These 8 EIP sites represented a 
surveillance catchment area of 9,667,103 persons in 2011.
Outcomes of Interest
Three separate outcome measures were evaluated: severe CDI disease, severe CDI outcome, 
and death within 14 days of infection. The definition of severe disease, adapted from current 
clinical practice guidelines [12], was development of ileus, toxic megacolon, or 
pseudomembranous colitis within 5 days of the positive C. difficile stool specimen or serum 
white blood count ≥15,000 cells/mm3 within one calendar day of collection of the stool 
specimen. Severe outcome was defined as intensive care unit (ICU) admission within 7 days 
after stool collection, colectomy for CDI, or death within 30 days of stool collection, in 
accordance with a recent study from Walk et al [7]. Death within 14 days was also evaluated 
based on the recent study from Walker et al [6].
Statistical Analysis
Multiple imputation was used to impute missing race (12.6% of cases) based on the 
distribution of known race by age, sex and surveillance site. Analysis of imputed datasets 
was performed using PROC MIANALYZE (SAS Institute, Cary, NC) to account for the 
uncertainty associated with imputation. Baseline differences between groups were evaluated 
using chi-square or Fisher exact tests for categorical variables, as appropriate, and Wilcoxon 
rank sum tests for continuous variables. Because a linear relationship between increasing 
Charlson index and outcome variables was seen (up to a Charlson comorbidity index of 3), 
the Charlson index was treated as an ordinal variable with levels 0, 1, 2, and ≥3.
For the outcomes studied, initial analyses of the association between individual variables 
and the outcome of interest were first performed with a univariate logistic regression model. 
Then a separate multivariate logistic regression model was constructed for each of three 
outcome measures of interest using stepwise backwards selection. Variables with P ≤ 0.25 in 
univariate analysis were eligible for inclusion in the corresponding multivariate model. 
Possible confounding variables (i.e., change of ≥ 10% to the estimated odds ratio for NAP 1 
strain) were added to respective multivariate models regardless of P values. Charlson index 
was also included in all models regardless of P value. To confirm the results found in 
multivariate models, analyses stratifying the data by age (patients ≤50 versus >50 years of 
age) and by epidemiologic classification (community-associated versus healthcare-
associated) were performed. A sensitivity analysis was also performed excluding the EIP 
site contributing the largest number of NAP1 cases from models. A 2-tailed P value of < 
0.05 was considered statistically significant. All analyses were performed with SAS 9.3 
(SAS Institute, Cary, NC).
Human Subjects
CDC and local institutional review boards approved the study. A waiver of informed 
consent was granted because the study posed no greater than minimal risk to participants.
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Description of Clostridium difficile Infection Cases
During 2009–2011, strain typing results were available for 2,057 of the 14,091 total CDI 
cases identified. Two EIP sites (New York and Minnesota) contributed >50% of cases with 
strain typing results (Table 1). Compared to CDI cases without strain typing results but with 
clinical data available (N=5,324), those with strain typing results were similar with respect 
to age (P=0.41) and the three clinical outcomes of interest: severe disease (P=0.05), severe 
outcome (P=0.90), and death within 14 days (P=0.18). Although differences in sex (P=0.04) 
and race (P<0.0001) between CDI cases with strain typing and those without strain typing 
results reached statistical significance, the relative differences were <6% between groups.
Among the 2,057 CDI cases included in the analysis, the majority (52.8%) were community-
associated by design. Overall, the most common strain types were: NAP1 (28.4% of cases), 
NAP4 (10.2%), NAP11 (9.1%), and NAP6 (6.6%) (Figure 1). Of the 585 NAP1 cases, 17 
(2.9%) were negative for binary toxin. Compared to these three most common NAP types, 
and compared to all others, the NAP1 type was associated with a greater odds of severe 
disease in unadjusted analysis. (Figure 2). Therefore, remaining analyses compare the NAP1 
strain to all other strain types (i.e., non-NAP1 strains).
NAP1 strain was associated with older age (P<0.0001), healthcare-associated epidemiologic 
classification (P<0.0001), emergency room visits (P=0.003) in the prior 12 weeks, Charlson 
index (P<0.0001), and prior receipt of antibiotics (P<0.0001) in univariate analysis (Table 
2). Inflammatory bowel disease (P=0.0003) and prior immunosuppressive treatment 
(P=0.04) were associated with non-NAP1 strains.
Outcomes
Severe disease—Criteria for severe disease were met for 363 cases (17.7%) with strain 
typing results. The majority of these cases (86.0%) met criteria for severe disease because of 
elevated white blood cell count alone. Infection with the NAP1 strain was significantly 
associated with severe disease in multivariate analysis (adjusted odds ratio [aOR] 1.74, 95% 
CI 1.36–2.22) after controlling for age, epidemiologic classification, prior emergency room 
visits and hospitalizations, Charlson index, prior immunosuppressive treatment, and prior 
antibiotic use (Table 3).
Severe outcome—Severe outcomes occurred for 100 cases (4.9%). Of these cases, 41 
were admitted to an ICU within 7 days after infection, 6 underwent colectomy, and 70 died 
within 30 days of infection. Cases developing severe outcomes were more likely to be 
infected with a NAP1 strain compared to those who did not develop severe outcomes 
(46.0% vs. 27.5%, P<0.0001). NAP 1 strain remained a predictor of severe outcomes in 
multivariate analysis (aOR 1.66, 95% CI 1.09–2.54) after controlling for older age, white 
race, healthcare-associated epidemiologic classification, Charlson index, and prior antibiotic 
use (Table 4).
Death within 14 days—Fifty-six deaths occurred within 14 days of stool collection. The 
NAP1 strain was more common among those who died within 14 days than among those 
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who survived (51.8% vs. 27.8%, P<0.0001). The 14-day mortality of NAP1 cases was 5.0% 
and for non-NAP1 cases was 1.8%. In particular, for NAP7/8 cases, which correspond to 
ribotype 078, the 14-day mortality was 1.5% (1 of 66 cases, 95% CI, 0.04%–8.0%). In 
univariate analyses, older age (OR 5.6, 95% CI 2.87–10.86), healthcare-associated 
epidemiologic classification (OR 5.41, 95% CI 2.43–12.07 for community-onset healthcare 
facility-associated vs community-associated; OR 10.38, 95% CI 4.59–23.43 for healthcare 
facility-onset vs community-associated), Charlson index (OR 2.68, 95% CI 1.94–3.70), prior 
proton pump inhibitor use (OR 2.18, 95% CI 1.28–3.71), and prior antibiotic use (OR 2.31, 
95% CI 1.30–4.11) were also associated with death within 14 days. In multivariate analysis, 
age, race, epidemiologic classification, and Charlson index were retained in the final model. 
After controlling for these risk factors, NAP1 strain remained a significant predictor of 14-
day mortality (aOR 2.12, 95% CI 1.22–3.68) (Table 5).
Sensitivity analyses—In analyses stratified by age group, NAP1 infection remained a 
predictor of poor outcomes in both younger (≤50 years) and older patients (>50 years) (data 
not shown). When stratifying by epidemiologic class (healthcare- vs. community-
associated), NAP1 remained significantly associated with the three outcomes of interest for 
healthcare-associated cases, while for community-associated cases, all NAP1 odds ratios 
were above 1.0 but P values were >0.05. Finally, the associations between the NAP1 strain 
and severe disease, severe outcome, and 14-day mortality remained significant after 
excluding cases from the EIP site (New York) that contributed the largest number of NAP1 
cases.
DISCUSSION
We found NAP1 to be the most common strain, accounting for over one-quarter of cases in 
our dataset. NAP1 was associated with greater odds of severe disease than other NAP types 
in unadjusted analysis and was also associated with older age and a variety of healthcare 
exposures. After controlling for potential confounders, the NAP1 strain remained a 
significant predictor of severe disease, severe outcome, and 14-day mortality. Our results 
represent the largest study to date to examine the association between strain type and disease 
outcomes. Furthermore, inclusion of cases from a wide geographic spread reduces bias due 
to regional variation in C. difficile strain type or patient characteristics.
We chose the outcome measures of severe outcome and 14-day mortality to facilitate 
comparisons with two recent studies on CDI outcome related to the NAP1 strain. Our 
findings agree with those in a recent report from the United Kingdom showing that the 
NAP1/027 strain is associated with increased 14-day mortality [5]. However, our results 
differ from a recent study from the United States by Walk et al that found no association 
between the NAP1/027 strain and severe outcome [7]. In the US study, the number of 
patients with NAP1 was small (~40) and fewer than 50 patients met the outcome measure. 
Though the US study reported a lack of association, the odds for severe outcome were 
increased among NAP1/027 cases, albeit not achieving statistical significance. Thus, as 
suggested by others [20, 21], lack of association between the NAP1/027 strain and severe 
outcome reported in the US study might be largely related to differences in sample size.
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The proportion of cases who died in our study (3.8%) is lower than that reported from other 
studies of CDI outcomes [6, 22]. This discrepancy is likely a result of a larger proportion of 
community-associated CDI cases in our study, which are associated with better outcomes 
than healthcare-associated cases [14]. This is unlikely to bias our study towards detection of 
association between strain type and outcomes, given that we adjusted for epidemiologic 
classification as a confounder in our analyses.
We found baseline differences between the patient populations infected by C. difficile NAP1 
versus non-NAP1 strains. Though we adjusted for patient comorbidities, unmeasured 
patient-level confounders might still account for some of the relationship we found between 
the NAP1 strain and patient outcomes. However, our findings persisted in analyses stratified 
by age, supporting that C. difficile strain is an important predictor of patient outcome 
independent of patient age. Associations between NAP1 strain and patient outcomes did not 
remain significant for community-associated cases when stratifying the data by 
epidemiologic classification. This lack of significance is likely related to low statistical 
power, as outcomes of interest were uncommon among community-associated cases (10.8% 
for severe disease, 1.5% for severe outcomes and 0.7% for death within 14 days), and the 
NAP1 strain was less prevalent in the community.
Our analysis therefore provides additional support for the conclusion that infection by the 
NAP1 strain adversely affects patient outcomes. The practical implications of this finding 
remain to be determined. Host-related factors play an important role in the development of 
CDI, and other studies have suggested that clinical scores or biomarkers based on the 
immune response of the host (e.g., albumin, serum white blood count, c-reactive protein), 
rather than strain type, should be the basis for decisions about severity of disease for 
treatment [12, 23, 24].
Nevertheless, strategies that account for strain-specific factors might complement treatment 
strategies based on host response and further reduce morbidity due to CDI. The specific 
virulence factors possessed by the NAP1/027 strain that lead to worsened outcomes still 
remain to be more clearly elucidated. As such research progresses, vaccines being developed 
for C. difficile might target such factors.
In addition, antimicrobial stewardship might further aid in preventing infections from the 
NAP1 strain. Although more judicious antimicrobial use would likely reduce C. difficile 
infections in general, including those caused by NAP1, stewardship efforts might also be 
leveraged to have a greater impact on NAP1 prevalence. For example, given that the 
NAP1/027 strain is more resistant than other strains to the fluoroquinolones [1, 3, 5, 25, 26], 
antimicrobial stewardship aimed at reducing the overall use of fluoroquinolones might also 
reduce the prevalence of infections from NAP1 and decrease patient morbidity from CDI. 
Indeed, fluoroquinolone use has been found to be a risk factor for infection by the 
NAP1/027 strain [27–29] and the development of fluoroquinolone resistance by the 
NAP1/027 strain has been suggested to be the primary genetic factor facilitating its spread 
[29]. Fluoroquinolone restriction has also been reported to be an important component of 
efforts to control outbreaks of C. difficile from the NAP1/027 strain [30, 31], but further 
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research is needed to determine the utility of the application of this strategy to non-outbreak 
settings.
We should note the following limitations of our study. First, all clinical data collected were 
obtained by retrospective review of medical charts. This potentially could have 
underestimated mortality rates if patients died soon after discharge. Second, we were not 
able to control for differences in treatment, which might affect patient outcomes. However, 
as noted earlier, because our data encompass a diverse geographic area, it is unlikely that our 
findings are driven by individual institutional treatment practices. Third, we could not fully 
evaluate the potential role of the NAP7/8/ribotype 078 strain, which has also been reported 
to have increased virulence [5, 32], on outcomes due to limited numbers of these cases in 
our dataset. Fourth, our analysis might not be representative of all C. difficile infections. For 
example, only a sample of healthcare facility-onset CDI cases are fully reviewed. However, 
even though cases with strain typing results represent a convenience sample of the total, 
comparison to cases without strain typing results suggests that our sample is representative 
of those cases with full medical record review. Fifth, we do not have data on all cases about 
the type of diagnostic test that was used to identify each CDI case (e.g., toxin assay versus 
nucleic acid amplification test [NAAT]). As CDI cases detected by toxin assays have been 
reported to have higher mortality than cases detected solely by NAAT [33], we could not 
account for this potential effect modifier of CDI outcomes.
In conclusion, analysis of a large, geographically diverse set of CDI cases from the United 
States corroborates that the C. difficile NAP1 strain type is an important determinant of 
patient outcomes. Disease from C. difficile results from a complex interplay between host-
related factors and pathogen-specific factors. Efforts to reduce the burden of CDI likely will 
need to consider both.
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Summary: After controlling for patient risk factors and healthcare exposures, NAP1 
Clostridium difficile strain type was associated with severe disease, severe outcome, and 
14-day mortality in multivariate models when compared to other strains types.
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Distribution of North American Pulsed-Field Gel Electrophoresis (PFGE) types among 
Clostridium difficile cases with strain typing results (n=2,057). Note that the “unnamed” 
strain type consists of many (>200) unrelated PFGE patterns.
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Univariate odds ratios for severe disease by strain type. NAP1 is the referent group, as 
indicated by the horizontal line at the odds ratio of 1.0. P values for all odds ratios depicted 
are < 0.05.
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Table 1
Clostridium difficile Infection (CDI) Cases with Strain Typing Results by Emerging Infections Program (EIP) 
site, 2009–2011
CDI Cases, All Strains
(n=2,057)
NAP1 Strain (n=585)
EIP Site No. of Cases % of Total No. of Cases % of Total
California 114 5.5 29 5.0
Colorado 346 16.8 103 17.6
Connecticut 184 9.0 82 14.0
Georgia 105 5.1 32 5.5
Minnesota 469 22.8 56 9.6
New York 689 33.5 242 41.4
Oregon 39 1.9 4 0.7
Tennessee 111 5.4 37 6.3
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Table 2
Univariate Comparison of Baseline Characteristics of Clostridium difficile Infection Due to the NAP1 Strain 









 Age > 65 years 305 (52.1) 586 (39.8) <0.0001
 Female sex 346 (59.2) 909 (61.8) 0.27
 White race 505 (86.4) 1262 (85.8) 0.74
Epidemiologic classification <0.0001
 Healthcare facility onset 111 (19.0) 211 (14.3)
 Community onset, healthcare facility-associated 232 (39.7) 416 (28.3)
 Community-associated 242 (41.4) 845 (57.4)
Healthcare exposures
 Chronic hemodialysis 39 (6.7) 68 (4.6) 0.06
 Surgery during 12 weeks prior to infection 130 (22.2) 285 (19.4) 0.15
 ER visits during 12 weeks prior to infection 224 (38.3) 462 (31.4) 0.003
Charlson comorbidity index <0.0001
 0 206 (35.2) 689 (46.8)
 1 81 (13.9) 169 (11.5)
 2 85 (14.5) 161 (10.9)
 ≥3 213 (36.4) 453 (30.8)
Other underlying conditions
 Diverticular disease 51 (8.7) 121 (8.2) 0.71
 Inflammatory bowel disease 11 (1.9) 90 (6.1) 0.0002
Medications during 14 days prior to infection
 Proton pump inhibitor 192 (32.8) 466 (31.7) 0.61
 H2 blocker 52 (8.9) 146 (9.9) 0.48
 Any immunosuppressive treatment 82 (14.0) 261 (17.7) 0.04
 Any antibiotic 345 (59.0) 691 (46.9) <0.0001
Abbreviations: ER, emergency room
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Table 3
Multivariate Analysis for Severe Clostridium difficile Disease Among Cases With Strain Typing Results, 
2009–2011
Cases With Strain Typing Results (n=2,057)
Risk Factors
a aOR (95% CI) P Value
Age > 65 years 1.69 (1.31–2.18) <0.0001
Healthcare-associated epidemiologic classification
b 1.75 (1.32–2.34) 0.0001
Emergency room visit during 12 weeks prior to infection 1.31 (1.01-1.69) 0.04
Charlson index 1.08 (0.98-1.20) 0.14
Medications during 14 days prior to infection
 Immunosuppressive treatment 1.42 (1.05-1.92) 0.02
 Any antibiotic 1.38 (1.08-1.76) 0.01
NAP1 strain 1.74 (1.36-2.22) <0.0001
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval
a
Candidate variables included in the severe disease model: age; epidemiologic classification; surgery or emergency room visit during 12 weeks 
prior to infection; diverticular disease; Charlson index; proton pump inhibitor use, immunosuppressive treatment, or antibiotic use during 14 days 
prior to infection; strain type.
b
Healthcare facility-onset and community-onset healthcare facility-associated epidemiologic classes did not have significantly different odds of 
severe disease and were collapsed into a single “healthcare-associated” category.
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Table 4
Multivariate Analysis for Severe Outcome of Clostridium difficile Infection Among Cases With Strain Typing 
Results, 2009–2011
Cases With Strain Typing Results (n=2,057)
Risk Factors
a aOR (95% CI) P Value
Age > 65 years 1.71 (1.06–2.76) 0.03
White race 0.49 (0.29–0.85) 0.01
Healthcare-associated epidemiologic classificationb 2.90 (1.63–5.19) 0.0003
Charlson index 1.71 (1.38–2.13) <0.0001
Any antibiotic during 14 days prior to infection 1.63 (1.04–2.56) 0.03
NAP1 strain 1.66 (1.09–2.54) 0.02
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval
a
Candidate variables included in the severe outcome model: age; race; epidemiologic classification; chronic hemodialysis; emergency room visit 
during 12 weeks prior to infection; Charlson index; proton pump inhibitor use, H2 blocker use, or antibiotic use during prior 14 days prior to 
infection; strain type.
b
Healthcare facility-onset and community-onset healthcare facility-associated epidemiologic classes did not have significantly different odds of 
severe outcome and were collapsed into a single “healthcare-associated” category.
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Table 5
Multivariate Analysis for 14-Day Mortality After Clostridium difficile Infection Among Cases With Strain 
Typing Results, 2009–2011
Cases With Strain Typing Results (n=2,057)
Risk Factors
a aOR (95% CI) P Value
Age > 65 years 2.98 (1.45–6.11) 0.003
White race 0.46 (0.23–0.95) 0.04
Epidemiologic classification
 Healthcare facility onset 3.80 (1.62–8.94) 0.002
 Community-onset healthcare facility-associated 2.33 (1.01–5.36) 0.05
 Community-associated (reference)
Charlson score 2.03 1.44–2.86) <0.0001
NAP1 strain 2.12 (1.22–3.68) 0.008
a
Candidate variables included in the model: age; race, epidemiologic classification; chronic hemodialysis; emergency room visit during 12 weeks 
prior to infection; Charlson index; proton pump inhibitor use, H2 blocker use, or antibiotic use during 14 days prior to infection; strain type.
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